Sonoma Pharmaceuticals price target lowered to $1.50 from $3.25 at Ladenburg

Ladenburg lowered the firm’s price target on Sonoma Pharmaceuticals to $1.50 from $3.25 and keeps a Buy rating on the shares following the fiscal 2024 report. With traction from the products launched during 2024, as well as the potential for new product launches or expansions, the firm anticipates ongoing revenue growth, the analyst tells investors in a research note.